Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 359 Issue 6396, 15 October 1992

Opinion

  • By charging drug companies 'user fees' that will be spent hiring new staff, the US Food and Drug Administration will reduce the time it takes to review new pharmaceuticals from an average of two years to one.

    Opinion

    Advertisement

  • Funding for a new programme, with only $1.5 million for grants, is hardly enough to scratch the surface.

    Opinion
  • Columbus, for all the criticism of the past few weeks, deserves his place in history.

    Opinion
Top of page ⤴

News

Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • "Improbability of effective vaccination against human immunodeficiency virus...",declares the title of a newpaper by Dr Albert Sabin. But three immunologists see flaws in his argument.

    • Gordon Ada
    • Bob Blanden
    • Arno Mullbacher
    Commentary
Top of page ⤴

Science in Japan

Top of page ⤴

News & Views

Top of page ⤴

Scientific Correspondence

Top of page ⤴

Book Review

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Guide to Authors

Top of page ⤴
Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links